Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Valleix F, Podoll T, Umezawa Y, Takao S, Iwata S, Hosono O, Taguchi T, Yamada T, Dang NH, Ohnuma K, Angevin E, Morimoto C.
Kaneko Y, et al. Among authors: morimoto c.
Biomark Res. 2021 Mar 23;9(1):21. doi: 10.1186/s40364-021-00273-0.
Biomark Res. 2021.
PMID: 33757558
Free PMC article.